CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2025.
Drug data last refreshed 42m ago · AI intelligence enriched 1mo ago
CARBON DIOXIDE, USP is an inhaled gas pharmaceutical approved as an X-ray contrast agent for diagnostic imaging procedures. It functions through X-ray contrast activity to enhance radiological visualization. This product represents a specialized medical gas with a narrow, diagnostic-focused indication set.
Recently approved product in early launch phase with moderate competitive pressure (30%) suggests a focused commercial build-out for a specialized diagnostic niche.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Join CARBON DIOXIDE, USP at launch stage with opportunity to build market presence in a specialized diagnostic segment. Currently zero linked job postings suggests early-stage hiring; roles will likely expand as commercial infrastructure scales.